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Abstract
Background: Current guidelines recommend glucocorticoids and splenectomy as standard 1st and 2nd line treatments for
chronic immune thrombocytopenia (ITP). We sought to find out how German ITP-patients are treated with respect to these
guidelines.
Methods: Members of a patient support association $18 years with a self-reported history of chronic ITP.12 months were
surveyed with a web-based questionnaire.
Results: 122 questionnaires were evaluated. 70% of patients had chronic ITP for more than 5 years and 20% an average
platelet count of #30?109/L. 41% of the patients reported haematomas or petechiae more than once or twice and up to 12
times or more per year and 17% oropharyngeal and nasal bleeds. 11% had been admitted to hospital during the last 12
months. 88% had received or currently receive glucocorticoids, 27% were splenectomised. IVIG had been given to 55%,
rituximab to 22%, anti-D to 12%, ciclosporin to 7%, while complementary and alternative medical treatments had been used
by 36%. 50 women responded to questions concerning pregnancy. 14 (28%) had been advised not to become pregnant. 23
reported pregnancies and 10 (44%) required treatment for their ITP during pregnancy.
Conclusion: Glucocorticoids are the most common therapy for chronic ITP but complementary and alternative treatments
already come second and less than M of patients are splenectomised. This and the frequent use of complementary
medicines suggests patients’ dissatisfaction with conventional approaches. Many patients receive off-label therapies. There
is a major need for adequate counselling and care for pregnant ITP-patients.
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Introduction
Chronic immune thrombocytopenia (ITP) is an acquired
disorder characterized by low platelet counts. Steroids are the
usual 1st-line treatment. Most patients respond with an initial
increase in counts but durable remissions are rare and thrombo-
cytopenia often recurs once steroid doses are tapered [1].
Splenectomy, thrombopoietin receptor agonists, and several other
treatments have been recommended for 2nd and 3rd line, but
experts opinions still differ about the optimal sequence of
therapeutic regimens. Treatment decisions are guided by physi-
cians’ personal preferences, cost considerations and various
regulatory limitations.
At the same time one has to keep in mind that despite the life-
threatening character of thrombocytopenia ITP-patients usually
do not succumb to their disease [2,3]. Many live with low platelet
counts for years and have remarkably little or even no bleeding
symptoms. This is in contrast to other haematologic disorders e.g.
lymphoma or leukaemia where a similar degree of thrombocyto-
penia almost always manifests with bleeding. Chronic ITP is a
disease of many years duration and patients have to weigh the
potential benefit of treatments against side effects and potential
limitations of occupation and daily activities.
Chronic ITP is a rare disorder. Recent studies found a
prevalence of 1 in 5.000 [4,5]. This makes ITP by definition an
orphan disease. Few physicians have personal experience in
treating large numbers of patients. Patient initiated self support
groups have been founded in the US, Britain and other countries.
Despite several guidelines published in the last years [6,7,8] it is
the experience of the authors that many patients are offered
treatments that do not follow recommendations, e.g. steroids are
prescribed for prolonged periods solely to keep platelet counts in a
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‘‘safe’’ range. We therefore concluded that there is a need for more
information about the long-term course and experience of ITP-
patients. In collaboration with the German ITP-patient support
group a questionnaire was developed and made available to the
members of the group. Survey items queried patient demographic
and clinical characteristics, treatment and side effects and impact
on daily functioning.
Methods
Procedure
A web-based questionnaire was designed based on clinical
literature, expert opinion and patients’ experience. After approval
from a central institutional review board, in accordance with the
Declaration of Helsinki, Good Clinical Practice guidelines, and
local laws and regulations survey participants were recruited from
the ‘‘Giessen ITP Support Group’’, a Germany based ITP-patient
support group. All participants were invited by mail or e-mail and
presented with an online opt-in consent before continuing with the
web-based questionnaire. Responses were anonymous to maintain
confidentiality.
Eligible study patients had to meet the following criteria:
– chronic ITP (defined as having the disease for no less than 12
months),
– 18 years of age or older.
Patients who did not fulfil the inclusion criteria were not
considered for the data analysis.
The questionnaire
The questionnaire had 45 questions and was divided into three
sections:
A. Personal and disease history (Q1–13). Age, gender,
duration of disease, platelet count and bleeding history. Patients
were asked to report their lowest, highest and ‘‘median’’ (as
estimated by the patient) platelet count in the last 12 months. Oral
or nasal mucosal bleeds were defined as wet purpura, petechiae
and ecchymoses/haematomas as dry purpura. We used these
terms because they were familiar to our patients from self support
group meetings.
B. Treatment history and experience with treatment
types (Q14–29). Corticosteroids, intravenous immunoglobulins,
azathioprin, rituximab, splenectomy, etc. including complementary
and alternative medicines (CAMs).
C. Effect of disease and treatment on daily activities
(Q30–45). Perceived limitations in occupation, recreational
activities, (only in women) pregnancy, utilization of medical
resources, etc.
Patients were given the option of selecting responses or
providing their own response in free form if none of the suggested
answers matched their personal experiences.
Statistics
Descriptive statistics were used to analyze data, Fisher’s exact
test for comparative testing. Statistical significance was set at a
two-sided 5% level. All statistical calculations were performed
using standard software (SAS WindowsTM, version 9.1).
Results
Fourhundred twenty patients were contacted by mail or e-mail,
133 responded (32%), 11 had to be excluded, mainly because of
age less than 18years. Overall 122 patients were included in the
analysis. General characteristics are given in Figure 1.
A. Personal and Disease History
Platelet Count. 48% of all patients reported that their lowest
platelet count during the preceding 12 months had been
#30?109/L, with 20% reporting their average platelet count to
be #30?109/L. The median platelet count below which patients
stated they would become concerned was #20?109/L.
Figure 1. Responses, exclusions and general characteristics of
the study population.
doi:10.1371/journal.pone.0027350.g001
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Bleeding History. Fifty patients (41%) reported petechiae or
haematomas (dry purpura) and 21 (17%) nasal and oral mucosal
bleeds (wet purpura) with a frequency of ‘more than just once or
twice’ up to ‘12 times or more during the last year’.
Correllation Platelet Count and Symptoms. Out of the
twenty-four patients (20%) reporting an average count #30?109/
L) 17 (71%) reported dry and 5 (21%) wet bleedings ‘more than
just once or twice’ up to ‘12 times or more during the last year’.
This means vice versa that 7 (29%) of severely thrombocytopenic
patients had up to one or two dry bleeds and 19 (79%) up to one or
two wet bleeds per year. Among 93 patients with higher counts
(average count .30?109/L) these numbers were 32 for dry (34%)
and 16 for wet bleeds (17%), respectively (comparison #30?109/L
vs. .30?109/L p= 0.002 for dry bleeds and p= 0.767 for wet
bleeds).
Out of the wenty-eight patients (23%) with an average count
.100?109/L during the last year, 6 (21%) reported dry and 2 (7%)
wet purpura with a frequency of ‘more than just once or twice’ up
to ‘12 times or more during the last year’.
Correllation Age and Symptoms. Thirty-six patients (30%)
were 60 years or older at the time of the survey. In this subgroup of
elderly patients 6 (17%) had an average count#30?109/L during the
last year with 8 (22%) reporting dry and 4 (11%) wet bleedings ‘more
than just once or twice’ or ‘12 times or more during the last year’. For
younger patients (,60 years) these numbers were 18 (21%), 41
(48%), and 17 (20%), respectively (comparison elderly vs. young
patients p= 0.021 for dry bleeds and p=0.425 for wet bleeds).
B. Treatment history and experience with treatment
types
Hospital Admissions. 11% of all patients had been admitted
to the hospital during the last 12 months, 3% even more than
twice. Of those with an average platelet count of #30?109/L, 13%
had been admitted to the hospital during the last 12 months and
12% of those with $30?109/L (comparison of patients with
#30?109/L vs. $30?109/L p= 1.00). 25% of patients older than
60 years had been admitted to hospital and 6% of those younger
than 60 years (comparison elderly vs. young p= 0.005). Of those
with ‘more than just one or two’ up to ‘12 or more’ dry bleeds
during the last year 10% had been admitted to the hospital during
the last 12 months and 13% of those with less bleeds (comparison
p= 0.775). For patients with ‘more than just one or two’ up to ‘12
or more’ wet bleeds these numbers were 19% and 10% for those
with less wet bleeds (comparison p= 0.269).
Therapy with Corticosteroids and other Agents. 88% of
patients stated that they have received corticosteroid therapy at
some point during their course of disease. 22% of the patients had
been treated with rituximab and 27% were splenectomised. The
numbers for those and other treatments are summarized in
figure 2. 36% of patients currently use or have used CAMs in the
past, among the elderly population this number was much lower
with only 8%. We conclude that elderly patients might have less
access to the internet and therefore might be less informed about
the use of CAMs. Another 7% of patients (n = 9) were treated with
‘‘other’’ treatment options, thereof e.g. platelet (n = 1) and
erythrocyte transfusions (n = 1), high dose vitamin C or change
in diet.
Thirty patients (28%) were on steroids during the three months
prior to the survey, despite a disease duration of 1 year or longer.
The most commonly reported severe side effects were weight gain
in 48%, moon face in 46%, and personality changes, mood swings
in 36%. 69% stated they would take steroids only if there was
absolutely no other option and 17% would not take steroids any
more at all.
27 patients had been treated with rituximab. 7% reported
severe infusion reactions and 52% stated they would try to avoid
or even refuse rituximab in the future. 33 patients had been
splenectomised, 58% of which would advise other patients against
this procedure. Following splenectomy, 42% of the patients had to
receive subsequent treatment with rituximab, IVIGs, etc.
Figure 2. Analysis of the question: ‘What treatments have you ever received for your immune thrombocytopenic purpura?’.
doi:10.1371/journal.pone.0027350.g002
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C. Effect of disease and treatment on daily activities and
pregnancies
11% of the patients felt ‘often’ or even ‘extremely’ affected by
their disease at school or occupational activities, 7% at daily non-
occupational activities. 13% of those patients with an average
platelet count of ,30?109/L and 12% of those with an average
count $30?109/L felt ‘often’ or ‘extremely’ limited at school/
occupational activities, 4% and 9% during daily non-occupational
activities, respectively. Statistical analysis did not show any
significant differences for patients with platelet counts ,30?109/
L vs. $30?109/L (comparison of impairment of occupational/
school activities p = 1.000, impairment of non-occupational
activities p = 0.68). 20% stated that they experienced problems
with health care coverage. 57% consulted a haematologist for their
disease while 16% saw a specialist for alternative medicine or did
not seek medical attendance at all.
50 women responded to questions concerning pregnancy. 14
(28%) stated that they had been advised not to become pregnant.
23 (19%) reported pregnancies and 10 (44%) were treated for their
ITP during pregnancy. 2 (9%) of the newborns had been
thrombocytopenic.
Discussion
ITP is an uncommon disorder. A prevalence of less than 1 in
5.000 [4] qualifies ITP as an orphan disease. Except for 1st-line
therapy with corticosteroids recommended by most national and
international guidelines there is no generally accepted treatment
consensus for 2nd- and 3rd-line treatment. There are few reports
about the long-term clinical course of chronic ITP except for
splenectomised patients [9,10] but splenectomised patients are a
minority among chronic ITP-patients. Only very recently patients’
perspective on treatment related side effects and quality of life has
moved into the focus of clinical research and guideline
development [11,12,13]. Our survey reveals
– that few patients with chronic ITP have severe bleeding
complications,
– that the hospital admission rate is not higher in ITP patients
with low platelet counts compared to higher platelet counts and
not higher in patients with frequent wet or dry bleeds
compared to those with rare or absent bleeds,
– that the hospital admission rate is higher in elderly patients
with ITP,
– that most patients have been treated with corticosteroids and
many still are even after one year,
– that side effects from corticosteroids are perceived as
particularly bothersome,
– that only a minority of patients with chronic ITP undergo
splenectomy,
– that many patients receive ‘‘off-label’’ therapies (e.g. rituximab,
cyclosporine, danazol),
– that even more than one third of patients uses complementary
and alternative medicines (CAMs).
In 1996, the ASH practice-guideline stated that ‘‘withholding
treatment was inappropriate for patients with a platelet count
#20?109/L, regardless of their symptoms’’ [7]. This same attitude
prevailed in the 2003 UK recommendations with a slightly higher
threshold of 30?109/L [6]. Both recommendations have lead
physicians to base treatment decisions solely on platelet counts.
The new international consensus report does not dismiss this
paradigm but notes that asymptomatic patients with platelets
.50?109/L rarely need therapy [8]. All these thresholds have been
arbitrarily defined based on expert opinion. Two retrospective
studies describe a correlation of bleeding events with patient age
.60 years and platelet counts,30?109/L [14,15]. However, none
of these studies records whether patients had severe bleedings
before and how their bleeding history predicts future events. One
of the studies also includes non-ITP-patients [15].
We assume that the number of hospital admissions might serve
as a surrogate marker for severe bleeding events (because those are
usually not treated as outpatients). Furthermore we observed that
patients with a low platelet count (,30?109/L) have more dry but
not more wet bleedings than patients with higher counts. The
reason for this difference is not clear. However, patients with low
counts do not have more hospital admissions than patients with
higher counts. Elderly patients are admitted more frequently but
this may have other reasons and need not be bleeding-related.
Together, these observations suggest that platelet counts correlate
with minor bleeding events (dry bleeds) but not with severe
bleedings.
Patients receive steroids for prolonged periods of time or they
are subjected to splenectomy solely to keep platelets above a
presumably safe threshold. A study in children shows that therapy
of low platelet counts had no effect on the subsequent development
of severe bleedings [16]. On the other hand several recent studies
in adults with chronic ITP find less severe bleeding when platelet
counts rise above 50?109/L [17,18]. However, these studies do not
address the question whether thrombocytopenic ITP-patients with
no or only minor bleeding benefit clinically from raising their
counts. The results of this survey support the recent German ITP
guideline recommendations to base treatment primarily on the
severity of clinical symptoms [19]. Khellaf et al. recommend to
base treatment decisions not on platelet count but clinical bleeding
signs [20]. Psaila et al. also find that intracranial haemorrhage in
children is not predicted by platelet count [21].
The new international consensus report recommends to grade
bleeding severity by counting petechiae and measuring the size of
haematomas [8,22]. Surprisingly among 28 patients who reported
their medium platelet count during a 12 month period to be over
100?109/L 6 (22%) respectively 2 (7%) stated they had dry and wet
purpura more than just once or twice a month. This might
indicate that treatment decisions should not be based on patient
reports of petechiae and haematomas, because the prognostic
relevance is not yet clear.
Almost all patients in this study had at some point received
corticosteroids, 28% were still taking steroids during the three
months before the survey (despite disease duration .1 year). 69%
stated that they would avoid steroids whenever possible, 17%
would not take them any more at all. The adverse effects most
often reported by patients were weight gain, moon face and mood
swings. This is in accordance with recent studies on quality of life
in ITP-patients [11,23,24].
As mentioned above the major complaints during steroid
treatment were weight gain, moon face and personality changes.
At the same time only 12% of patients were bothered by severe
gastric symptoms, 9% reported severe hypertension, and 3%
severe hyperglycemias. This contrasts with physicians’ perception
of steroid side effects. Patients are usually informed about the risks
of ulcers, hypertension, infections and diabetes. Weight gain is
generally not considered a contraindication by physicians. There
has been a similar observation in cancer patients who rank side
effects differently than their physicians and who are often
dissatisfied with the handling of treatment-related toxicities [25].
Of notice, despite guideline recommendation only 27% of
patients had been splenectomised. On the other hand 44% of
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patients received ‘‘off-label’’ drugs (22% rituximab, 11% anti-D,
7% ciclosporin, 4% danazol), when only the following drugs were
approved in Germany for the treatment of immune thrombocy-
topenia: steroids, immunoglobulins, azathioprine, thrombopoietin
receptor agonists and vinca alkaloids. The rate of splenectomies is
low, not only in Germany, but also in other countries [26,27]. This
observation suggests that patients are willing to accept even
unlicensed therapies to avoid surgery. The recently introduced
term ‘‘splenectomy-sparing therapy’’ indicates that avoidance of
splenectomy has become a valuable therapeutic goal [28]. German
public health insurance usually does not cover cost for unlicensed
therapies. A previous survey conducted 5 years earlier had shown
that almost 40% of patients had the feeling that financial
capabilities affected treatment recommendations [29]. In this
study still 20% report problems with cost coverage. Most recently,
thrombopoietin receptor agonists have been denied approval in
Europe for 2nd-line therapy in patients without splenectomy
(except for when splenectomy is contraindicated) despite phase III
data showing efficacy. All this could add to the frustration of
patients and partially explains the frequent use of CAMs, which
are widely used after corticosteroids, more often than any other
evidence-based treatment.
Severe maternal or neonatal bleedings are rare when pregnant
women with chronic ITP are managed by a multiprofessional
team [30]. In this study were 77 women, of whom 50 responded to
questions concerning pregnancy and ITP. Many reported that
they had been advised not to become pregnant. 10 of 23 women
(43%) received treatment for thrombocytopenia during pregnancy.
Two of the newborns were thrombocytopenic. There is an urgent
need for clinical centres with gynaecologists and haematologists
experienced in the treatment of chronic ITP and providing
24 hour service to pregnant women with ITP.
Our study has several limitations. All participants were recruited
from the register of an ITP self support group and retrospectively
reported on their course of disease. Patients in self support groups
have usually received - and failed - several lines of therapy and are
therefore more critical to the efficacy and side effects of therapies.
We also cannot exclude that the web-based format of this survey
has deterred some elderly or less capable patients. However, the
percentage of Germans using the internet is constantly growing,
with the highest growth rates in the elderly population. With
regards to age and gender this survey seems comparable to other
publications [4,27]. The members of the Giessen ITP support-
group are usually mobile and able to attend the annual group
meeting. We assume that this study has a pre-selection bias
because patients with more severe, debilitating or lethal bleedings
might be underrepresented. It was not the purpose of this study to
give a representative picture of all chronic ITP-patients in
Germany, but rather from a large and clinically relevant group
(to our knowledge this is the only German ITP support group with
a considerable number of members (n,500)). Even if some
patients with severe disease were not included this does not
devaluate the experiences of the majority of patients.
In the results section we report patients’ statements about the
frequency of dry and wet bleedings. We are aware that it is difficult
for patients to identify dry and wet bleedings.
In conclusion, this study reveals that most chronic ITP-patients
have a benign clinical course. Low platelet count and frequency of
wet and dry purpura do not predict a higher risk of hospital
admissions, but age does. Glucocorticoids are still the most
common therapy for chronic ITP and often used for prolonged
periods. Complementary and alternative treatments already come
second and less than M of the patients are splenectomised. Many
patients receive off-label treatments. The frequent use of
complementary medicines suggests dissatisfaction with conven-
tional health care. There is a major need for adequate counselling
and care for pregnant ITP-patients.
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